Zacks Investment Research downgraded shares of AveXis, Inc. (NASDAQ:AVXS) from a buy rating to a hold rating in a report published on Monday morning.

According to Zacks, “AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company’s product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. “

Several other research analysts have also commented on AVXS. Canaccord Genuity initiated coverage on AveXis in a research note on Thursday, October 26th. They set a hold rating and a $110.00 target price for the company. Sanford C. Bernstein initiated coverage on AveXis in a research note on Thursday, July 27th. They set an outperform rating and a $108.00 target price for the company. Citigroup Inc. raised their target price on AveXis from $100.00 to $116.00 and gave the company a buy rating in a research note on Monday, October 2nd. UBS AG restated a buy rating and set a $122.00 target price (up from $95.00) on shares of AveXis in a research note on Tuesday, October 3rd. Finally, Nomura initiated coverage on AveXis in a research note on Monday, August 28th. They set a reduce rating and a $52.00 target price for the company. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the company’s stock. AveXis has a consensus rating of Buy and an average target price of $107.78.

Shares of AveXis (AVXS) traded up $4.61 during trading on Monday, hitting $104.53. The company’s stock had a trading volume of 342,720 shares, compared to its average volume of 323,659.

AveXis (NASDAQ:AVXS) last issued its earnings results on Thursday, August 10th. The company reported ($2.07) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($1.10). During the same period last year, the firm earned ($0.68) earnings per share. analysts anticipate that AveXis will post -5.55 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “AveXis, Inc. (AVXS) Rating Lowered to Hold at Zacks Investment Research” was posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.watchlistnews.com/avexis-inc-avxs-rating-lowered-to-hold-at-zacks-investment-research/1676670.html.

In related news, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $93.25, for a total transaction of $165,985.00. Following the sale, the vice president now owns 1,780 shares of the company’s stock, valued at $165,985. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Brian K. Kaspar sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $101.46, for a total value of $1,521,900.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 35,340 shares of company stock valued at $3,559,683. 18.60% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of the business. Candriam Luxembourg S.C.A. grew its position in AveXis by 14.0% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 28,500 shares of the company’s stock worth $2,757,000 after purchasing an additional 3,500 shares in the last quarter. Smith Asset Management Group LP purchased a new position in AveXis during the 3rd quarter worth approximately $516,000. Prudential Financial Inc. purchased a new position in AveXis during the 3rd quarter worth approximately $224,000. American Century Companies Inc. purchased a new position in AveXis during the 3rd quarter worth approximately $1,450,000. Finally, State Board of Administration of Florida Retirement System grew its position in AveXis by 19.1% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 12,968 shares of the company’s stock worth $1,254,000 after purchasing an additional 2,080 shares in the last quarter. Hedge funds and other institutional investors own 94.71% of the company’s stock.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Get a free copy of the Zacks research report on AveXis (AVXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.